Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Investigating biomarkers of Phase II endocrine resistance in breast cancer

A postgraduate research opportunity at the University of Otago.

Details

Close date
Thursday, 30 April 2020
Academic background
Sciences, Health Sciences
Host campus
Dunedin
Location
On-campus
Qualification
Master’s
Department
Pathology (DSM)
Supervisor
Dr Heather Cunliffe

Overview

Phase II endocrine resistance is a phenomenon observed in a proportion of breast cancer patients following long term estrogen deprivation therapy, whereupon re-exposure to a short-term pulse of physiological estrogen causes their tumours to apoptose. Moreover, this treatment results in resensitisation of tumour cells to anti-estrogen threapy.

This project will leverage laboratory models of Phase II resistant breast cancer to investigate genes and cellular pathways altered in phase II vs. Phase I (estrogen-stimulated) disease. Findings will contribute to an ongoing international collaborative study to define translational biomarkers to identify patients whose disease has evolved from phase I to Phase II resistance.

Contact

Heather Cunliffe
Email   heather.cunliffe@otago.ac.nz